Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma : Updated Overall Survival, Safety, and Subgroups - Orlowski, Robert Z. (Department of Lymphoma and Myeloma. The University of Texas M.D. Anderson Cancer Center) ; Moreau, Philippe (Department of Hematology. University Hospital Hotel-Dieu) ; Niesvizky, Ruben (Department of Medical Oncology. Myeloma Center. New York Presbyterian Hospital-Weill Cornell Medical Center) ; Ludwig, Heinz (Wilhelminen Cancer Research Institute (Viena, Àustria)) ; Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Chng, Wee Joo (Department of Hematology Oncology. National University of Singapore) ; Goldschmidt, Hartmut (Department of Hematology Oncology. Heidelberg University Clinic and the National Center of Tumor Diseases) ; Yang, Zhao (Department of Biostatistics. Amgen. Inc) ; Kimball, Amy S. (Department of Clinical Research. Amgen. Inc) ; Dimopoulos, Meletios (Department of Clinical Therapeutics. University Athens School of Medicine) ; Universitat Autònoma de Barcelona